Integrating HTS and Fragment-based Drug Discovery By Dr John Barker, Dr Thomas Hesterkamp and Dr Mark Whittaker High-Throughput Screening and Fragment Based Drug Discovery have been considered as alternative approaches to drug discovery for enzyme targets. HTS tends to be a rather quick way of identifying potent chemical matter with… Read More
Data Overflow Progress in Automating and Streamlining Data By Peer Staehler The genomic world moves faster and faster. The pool of data has exploded exponentially in the past few years due to the growing knowledge about the relevance of genomic findings for medicine and the environment. Like all other developing… Read More
Transcending Proteasome Inhibition for the Treatment of Cancer By Dr Mark Rolfe Healthy cellular function requires a carefully controlled balance between protein synthesis and protein degradation, a process known as protein homeostasis. The major intracellular pathway for controlling protein degradation is the ubiquitin proteasome system (UPS). Specific pharmacological inhibition of… Read More
Screening the Human Kinome - Expectations Met or Promises Pending? By Dr Richard M. Eglen Protein kinases are important targets in drug discovery programmes aimed at treating cancer, autoimmune disorders, diabetes and neurological disorders. Novel information on kinase biology is opening up other approaches in the design of selective inhibitors… Read More
HIV Therapy - Past, Present and Future By Dr Laura Waters Since the identification of HIV in 1983 and licensing of AZT in 1986 we now have more than 20 agents available for HIV treatment from five drug classes. This article will review recent advances in HIV treatment and discuss… Read More
The Potential of Molecular Imaging for Drug Discovery & Development By Dr Ken Rubenstein By combining cutting-edge biomedical research with the time-proven ability to visualise the unseen, the rapidly emerging field of molecular imaging promises to open new vistas for a wide range of individuals, from basic researchers to scientists… Read More
Is Amyloid-related Toxicity an Inevitable Consequence of Ageing? By Dr J Mark Treherne and Dr David IC Scopes Amyloid-related toxicity need not necessarily be the inevitable consequence of ageing, if some of the new drug discovery strategies to treat neurodegenerative and other ageing-related diseases succeed in the clinic. An increasing… Read More
Dispense and Imaging Assays - Moving towards a more balanced use of both fluorescence and flash luminescent readouts By Dr John Comley Progress towards the uptake and adoption of flash luminescence readouts in screening were the subject of HTStec's recent Dispense & Imaging (D&I) Trends 2007 report. The report suggests… Read More
The Importance of Liquid Handling Quality Assurance in Drug Discovery By Dr Nathaniel G Hentz The tug-of-war between quality and productivity is an issue facing all drug discovery companies, competing in a fierce race to bring breakthrough drugs to market before the competition. With the advance of laboratory automation… Read More
Advances in Antibody Therapy - A promising new approach to how we treat cancer By Dr Patrick A Baeuerle Antibodies available today for cancer treatment, while effective, are typically used in combination with standard therapies because their activity as monotherapy is limited. Currently, four conventional antibody products dominate the oncology… Read More
Lean Six Sigma - Its application to drug discovery By Clare Hammond and Charles J O'Donnell In an increasingly competitive world, the race between pharmas to get high quality candidate drugs to market is on. Contributing to this success is the discovery phase of lead optimisation. The application of Lean… Read More
Progress in Systems-Based Analysis of Cellular Signalling By Dr Jeffrey A. Radding Drug discovery currently focuses on targeted approaches, relying on validation of the target as a disease driver. However, the underlying biological complexity of disease often frustrates these attempts at therapeutic intervention, resulting in high failure rates due to… Read More
Needs and challenges in High Throughput Screening By William Downey, Dr Helen Nicely and Dr Lynne Sopchak High throughput screening (HTS) groups face similar challenges as the pharmaceutical and biotechnology industry as a whole faces. HTS groups are looking for ways to improve effectiveness in lead discovery, increase their productivity… Read More
Microplate Mixing - Bioassay panacea or of unproven distraction? By Dr John Comley Despite general awareness of the significance of microplate mixing, it is still a relatively low priority in most laboratories. Microplate mixing has largely been ignored as a serious problem, although potentially it could undermine the generation of… Read More
Human ES Cell Derived Functional Cells as Tools in Drug Discovery By Dr Petter Bjorquist, Dr Peter Sartipy, Dr Raimund Strehl and Dr Johan Hyllner The drug discovery process is extremely-time consuming and expensive. Consequently, novel approaches for these processes and for reducing late-stage attrition are of great value for… Read More
Perspectives for ADMET Integration in the Discovery Process By Dr Constance Hofer ADMET (ADME/Tox), is a relatively new symbiotic acronym for the investigation of basic compound behaviour in terms of absorption, distribution, metabolism and excretion, combined with assessments of toxicity. The emergence of ADMET instead of ADME reflects the growing… Read More